---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052111"
form_type: "8-K"
ticker: null
cik: "0001832168"
company_name: "Longboard Pharmaceuticals, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:50:48.943661+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Longboard Q1 2024: $321M cash; bexicaserin Phase 3 on track for YE 2024

## Summary
- Cash, cash equivalents and investments of $321.0M as of March 31, 2024; cash runway into 2027.
- Net proceeds of $226.5M from Jan 2024 follow-on offering (11.5M shares at $21.00) and $59.9M from private placement (2.85M non-voting shares at $21.00).
- R&D expenses $13.2M (+54% YoY), primarily due to bexicaserin and LP659 trial costs.
- Positive topline PACIFIC Study data for bexicaserin presented at AAN April 2024; global Phase 3 to start by YE 2024.
- LP659 Phase 1 SAD topline data expected Q2 2024; PACIFIC open-label extension data in H2 2024.

## SEC filing metadata
- accession: 0000950170-24-052111
- form_type: 8-K
- cik: 0001832168
- company_name: Longboard Pharmaceuticals, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/0000950170-24-052111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/lbph-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052111
- JSON: https://secwatch.observer/filing/0000950170-24-052111.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052111.txt

## Key facts
- Earnings Releases
  Longboard Pharmaceuticals, Inc. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: On May 2, 2024, Longboard Pharmaceuticals, Inc. ("Longboard") issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832168/000095017024052111/0000950170-24-052111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.